Pfizer and BioNTech’s BNT162b2 Demonstrates 95% Efficacy in Preventing COVID-19

 Pfizer and BioNTech’s BNT162b2 Demonstrates 95% Efficacy in Preventing COVID-19

Pfizer and BioNTech’s BNT162b2 Demonstrates 95% Efficacy in Preventing COVID-19

Shots:

  • The primary efficacy analysis demonstrated that BNT162b2 is 95% effective against COVID-19 beginning 28 days after the first dose. The study evaluated 170 confirmed cases of COVID-19 with 162 in PBO group vs 8 in the vaccine group
  • The observed efficacy in adults over 65yrs. of age was ~94% and was well tolerated across all populations with ~43,000 participants, no serious safety concerns were observed
  • The companies plan to submit the data within days to the FDA for EUA and share data with other regulatory agencies across the globe and expect to produce globally ~50M vaccine doses in 2020 and ~1.3B doses by the end of 2021

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Pfizer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post